Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Acitretin

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    15 result(s) found for: Acitretin. Displaying page 1 of 1.
    EudraCT Number: 2009-011881-27 Sponsor Protocol Number: ADAM Start Date*: Information not available in EudraCT
    Sponsor Name:University Medical Center of the Johannes Gutenberg-University Mainz
    Full Title: Changes of cerebral spinal fluid APPSα levels under oral therapy with acitretin 30 mg daily in patients with mild to moderate Alzheimer’s disease: a multicenter prospective randomised placebo-contr...
    Medical condition: Alzheimer’s disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2006-004519-23 Sponsor Protocol Number: 08/08 Start Date*: 2009-03-19
    Sponsor Name:Medizinische Universität Wien, Univ.Klinik für Dermatologie
    Full Title: Comparison of fumaric acid ester-PUVA versus PUVA-etretinate in palmoplantar pustolosis
    Medical condition: Psoriasis pustulosis palmoplantaris
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2005-000707-34 Sponsor Protocol Number: 2316 Start Date*: 2011-11-08
    Sponsor Name:The Newcastle upon Tyne Hospitals NHS Trust
    Full Title: The induction of apoptosis by anti-psoriatic treatments
    Medical condition: Psoriasis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-006227-31 Sponsor Protocol Number: 0881X1-4503 Start Date*: 2009-01-09
    Sponsor Name:Medical Faculty, Otto-von-Guericke-University Magdeburg
    Full Title: Inflammatory Topoproteome of Psoriasis under Etanercept Treatment
    Medical condition: Patients with a severe psoriasis will be treated with Enbrel (Etanercept) 2 x 50 mg s.c. per week over 12 weeks (n = 6 patients). The treatment follows rigorously the approved label of the drug. Th...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2010-018279-99 Sponsor Protocol Number: HUM07-066 Start Date*: 2010-05-05
    Sponsor Name:Faculty of Medicine, Otto-von-Guericke-University Magdeburg
    Full Title: Skin Topoproteome under Adalimumab (Humira®) Treatment in Patients with Moderate to Severe Psoriasis
    Medical condition: Disease under investigation: Adult patients of both genders with moderate to severe chronic plaque psoriasis who failed to respond to or who have a contraindication to, or are intolerant to other s...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2005-005936-29 Sponsor Protocol Number: 0881A6-318-EU Start Date*: 2006-09-28
    Sponsor Name:Wyeth Research Division of Wyeth Pharmaceuticals Inc. Clinical research and Development [...]
    1. Wyeth Research Division of Wyeth Pharmaceuticals Inc. Clinical research and Development
    2. Wyeth Pharmaceuticals France, Wyeth Research Division
    Full Title: A Multicenter, Parallel, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of Etanercept 50 mg Once Weekly in Subjects With Moderate to Severe Plaque Psoriasis
    Medical condition: moderate to severe plaque psoriasis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) BE (Completed) ES (Completed) NL (Completed) DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-019129-32 Sponsor Protocol Number: pRGF/009/10 Start Date*: 2010-04-30
    Sponsor Name:University of Aberdeen
    Full Title: Enumeration and Functional Evaluation of Regulatory T-cells in Psoriasis Patients Before and After Treatment with: Calcipotriol/Betamethasone, Acitretin, Narrow-Band UVB and Anti-TNF α Therapy (Eta...
    Medical condition: This research will be conducted on Dermatology patients diagnosed with "psoriasis" which is a common skin problem adversly affects the quality of life of affected patients.
    Disease: Version SOC Term Classification Code Term Level
    12.1 10037153 Psoriasis LLT
    12.1 10050576 Psoriasis vulgaris LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-023901-36 Sponsor Protocol Number: UHK-GMD-LOA-04 Start Date*: 2011-04-12
    Sponsor Name:Faculty of Medicine, Otto-von-Guericke-University, Magdeburg
    Full Title: Psoriasis-topoproteome under ustekinumab treatment (PIROUETTE-Study) - as an interventional observation study (phase IV) within approved label and indication and with minimal invasive taking of ski...
    Medical condition: STELARA™ as IMP will be used in all relevant aspects (indication, contraindications, dosing) completely within the approved label, namely for the treatment of adult patients with moderate to severe...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2010-018517-29 Sponsor Protocol Number: DMD-UHK-B1 Start Date*: 2010-02-22
    Sponsor Name:Medical Faculty, Otto-von-Guericke-University Magdeburg
    Full Title: Topoproteome-Analysis of Psoriasis under Fumarate-Treatment.
    Medical condition: Fumaderm initial / Fumaderm will be used in this CT completely "in-label", i.e. for the treatment of adult patients of both genders with moderate to severe plaque psoriasis in so far as a solely to...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-002612-14 Sponsor Protocol Number: TMP-0517 Start Date*: 2019-06-25
    Sponsor Name:Fraunhofer Gesellschaft for its Institute Fraunhofer Institute for Molecular Biology and Applied Ecology (IME)
    Full Title: Preliminary efficacy and safety of Apremilast in the treatment of acne conglobata: A phase II, single centre, open label, proof of concept study for the treatment of acne conglobata with the PDE-4 ...
    Medical condition: Mild to severe Acne conglobata in adults (ages 18 to 65 years, inclusive)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10000501 Acne conglobata PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-001368-40 Sponsor Protocol Number: M-41008-41 Start Date*: 2017-09-13
    Sponsor Name:Almirall S.A.
    Full Title: Open clinical study to assess long-term efficacy and safety of dimethyl fumarate in adults with moderate to severe chronic plaque psoriasis in real practice (DIMESKIN 1 Trial)
    Medical condition: Moderate-severe chronic plaque psoriasis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10037153 Psoriasis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2017-003818-11 Sponsor Protocol Number: M-41008-42 Start Date*: 2018-03-12
    Sponsor Name:ALMIRALL SPA
    Full Title: An open-label clinical study to evaluate the long-term efficacy and tolerability of treatment with dimethyl fumarate (DMF) in adults with chronic plaque psoriasis (Study DIMESKIN 2).
    Medical condition: chronic plaque psoriasis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10071117 Plaque psoriasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2008-004439-39 Sponsor Protocol Number: 0881X1-4535-WW Start Date*: 2009-12-22
    Sponsor Name:Wyeth Research Division of Wyeth Pharmaceuticals Inc. A Pfizer Company,Philadelphia,PA-19101,USA
    Full Title: Randomized Open-label Study Comparing 2 Different Strategies For Management of Subjects With Plaque Psoriasis Who Have Responded to Etanercept Treatment
    Medical condition: Plaque psoriasis
    Disease: Version SOC Term Classification Code Term Level
    14.0 10040785 - Skin and subcutaneous tissue disorders 10037153 Psoriasis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) HU (Completed) FR (Completed) GR (Completed) DE (Completed) ES (Completed) PT (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2012-002798-80 Sponsor Protocol Number: IM101-332 Start Date*: 2013-08-02
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase 3 Randomized Placebo Controlled Study to Evaluate the Efficacy and Safety of Abatacept Subcutaneous Injection in Adults with Active Psoriatic Arthritis
    Medical condition: Active Psoriatic Arthritis
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004859 10037160 Psoriatic arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) DE (Completed) GR (Completed) IT (Completed) CZ (Completed) PL (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2018-002850-58 Sponsor Protocol Number: CC-10004-PSOR-020 Start Date*: 2019-02-19
    Sponsor Name:Amgen Inc.
    Full Title: A PHASE 4, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE IMPACT OF APREMILAST (CC-10004) ON QUALITY OF LIFE, EFFICACY, AND SAFETY IN SUBJECTS WITH MANIFESTATIONS OF PLAQUE...
    Medical condition: Plaque Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10071117 Plaque psoriasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 29 20:16:17 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA